Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer

Hideaki Kunugasa, Kazuhiro Nouso, Soichiro Ako, Chihiro Dohi, Hiroshi Matsushita, Kazuyuki Matsumoto, Hironari Katou, Hiroyuki Okada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Tissue sampling of gallbladder cancer (GBCa) is challenging because of the anatomy of the gallbladder. The aim of this study is to investigate the possibility of diagnosing GBCa patients by performing a liquid biopsy of bile in addition to current diagnostic methods. Methods: Thirty patients with GBCa were enrolled in this study. Cytological examination was performed in all patients. Using next generation sequencing (NGS), DNA isolated from the bile and tumor tissue was analyzed for mutations in 49 oncogenes. We also compared these mutations with cytology results. Results: 57.1% of DNA samples from tumor tissue were positive for a mutation. In these patients, 87.5% of the bile circulating tumor DNA (ctDNA) samples had the same mutation. The concordance rate between bile ctDNA and tissue DNA samples was 85.7%, and the mutation frequencies detected in ctDNA were approximately half of what was detected in tumor tissue DNA. On the other hand, the sensitivity of the cytological and bile ctDNA analyses was 45.8% and 58.3%, respectively. The concordance rate between cytology and bile ctDNA analyses was 87.5%. Conclusions: Mutated tumor DNA could be detected in bile by NGS. Liquid biopsy of bile might help us to diagnose GBCa because of higher sensitivity and positive predict value compared to cytology with ERCP.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalCancer Biology and Therapy
DOIs
Publication statusAccepted/In press - Apr 20 2018

Fingerprint

Gallbladder Neoplasms
Bile
Biopsy
DNA
Neoplasms
Cell Biology
Mutation
Endoscopic Retrograde Cholangiopancreatography
Mutation Rate
Gallbladder
DNA Sequence Analysis
Oncogenes
Anatomy

Keywords

  • bile
  • circulating tumor DNA
  • CtDNA
  • gallbladder cancer
  • liquid biopsy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer. / Kunugasa, Hideaki; Nouso, Kazuhiro; Ako, Soichiro; Dohi, Chihiro; Matsushita, Hiroshi; Matsumoto, Kazuyuki; Katou, Hironari; Okada, Hiroyuki.

In: Cancer Biology and Therapy, 20.04.2018, p. 1-5.

Research output: Contribution to journalArticle

@article{c1984ddddeb049dc841de09486bacbda,
title = "Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer",
abstract = "Introduction: Tissue sampling of gallbladder cancer (GBCa) is challenging because of the anatomy of the gallbladder. The aim of this study is to investigate the possibility of diagnosing GBCa patients by performing a liquid biopsy of bile in addition to current diagnostic methods. Methods: Thirty patients with GBCa were enrolled in this study. Cytological examination was performed in all patients. Using next generation sequencing (NGS), DNA isolated from the bile and tumor tissue was analyzed for mutations in 49 oncogenes. We also compared these mutations with cytology results. Results: 57.1{\%} of DNA samples from tumor tissue were positive for a mutation. In these patients, 87.5{\%} of the bile circulating tumor DNA (ctDNA) samples had the same mutation. The concordance rate between bile ctDNA and tissue DNA samples was 85.7{\%}, and the mutation frequencies detected in ctDNA were approximately half of what was detected in tumor tissue DNA. On the other hand, the sensitivity of the cytological and bile ctDNA analyses was 45.8{\%} and 58.3{\%}, respectively. The concordance rate between cytology and bile ctDNA analyses was 87.5{\%}. Conclusions: Mutated tumor DNA could be detected in bile by NGS. Liquid biopsy of bile might help us to diagnose GBCa because of higher sensitivity and positive predict value compared to cytology with ERCP.",
keywords = "bile, circulating tumor DNA, CtDNA, gallbladder cancer, liquid biopsy",
author = "Hideaki Kunugasa and Kazuhiro Nouso and Soichiro Ako and Chihiro Dohi and Hiroshi Matsushita and Kazuyuki Matsumoto and Hironari Katou and Hiroyuki Okada",
year = "2018",
month = "4",
day = "20",
doi = "10.1080/15384047.2018.1456604",
language = "English",
pages = "1--5",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer

AU - Kunugasa, Hideaki

AU - Nouso, Kazuhiro

AU - Ako, Soichiro

AU - Dohi, Chihiro

AU - Matsushita, Hiroshi

AU - Matsumoto, Kazuyuki

AU - Katou, Hironari

AU - Okada, Hiroyuki

PY - 2018/4/20

Y1 - 2018/4/20

N2 - Introduction: Tissue sampling of gallbladder cancer (GBCa) is challenging because of the anatomy of the gallbladder. The aim of this study is to investigate the possibility of diagnosing GBCa patients by performing a liquid biopsy of bile in addition to current diagnostic methods. Methods: Thirty patients with GBCa were enrolled in this study. Cytological examination was performed in all patients. Using next generation sequencing (NGS), DNA isolated from the bile and tumor tissue was analyzed for mutations in 49 oncogenes. We also compared these mutations with cytology results. Results: 57.1% of DNA samples from tumor tissue were positive for a mutation. In these patients, 87.5% of the bile circulating tumor DNA (ctDNA) samples had the same mutation. The concordance rate between bile ctDNA and tissue DNA samples was 85.7%, and the mutation frequencies detected in ctDNA were approximately half of what was detected in tumor tissue DNA. On the other hand, the sensitivity of the cytological and bile ctDNA analyses was 45.8% and 58.3%, respectively. The concordance rate between cytology and bile ctDNA analyses was 87.5%. Conclusions: Mutated tumor DNA could be detected in bile by NGS. Liquid biopsy of bile might help us to diagnose GBCa because of higher sensitivity and positive predict value compared to cytology with ERCP.

AB - Introduction: Tissue sampling of gallbladder cancer (GBCa) is challenging because of the anatomy of the gallbladder. The aim of this study is to investigate the possibility of diagnosing GBCa patients by performing a liquid biopsy of bile in addition to current diagnostic methods. Methods: Thirty patients with GBCa were enrolled in this study. Cytological examination was performed in all patients. Using next generation sequencing (NGS), DNA isolated from the bile and tumor tissue was analyzed for mutations in 49 oncogenes. We also compared these mutations with cytology results. Results: 57.1% of DNA samples from tumor tissue were positive for a mutation. In these patients, 87.5% of the bile circulating tumor DNA (ctDNA) samples had the same mutation. The concordance rate between bile ctDNA and tissue DNA samples was 85.7%, and the mutation frequencies detected in ctDNA were approximately half of what was detected in tumor tissue DNA. On the other hand, the sensitivity of the cytological and bile ctDNA analyses was 45.8% and 58.3%, respectively. The concordance rate between cytology and bile ctDNA analyses was 87.5%. Conclusions: Mutated tumor DNA could be detected in bile by NGS. Liquid biopsy of bile might help us to diagnose GBCa because of higher sensitivity and positive predict value compared to cytology with ERCP.

KW - bile

KW - circulating tumor DNA

KW - CtDNA

KW - gallbladder cancer

KW - liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85046399409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046399409&partnerID=8YFLogxK

U2 - 10.1080/15384047.2018.1456604

DO - 10.1080/15384047.2018.1456604

M3 - Article

C2 - 29580156

AN - SCOPUS:85046399409

SP - 1

EP - 5

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

ER -